Last reviewed · How we verify

EZN-2208, Cetuximab and Irinotecan

Enzon Pharmaceuticals, Inc. · Phase 2 active Small molecule

EZN-2208, Cetuximab and Irinotecan is a Small molecule drug developed by Enzon Pharmaceuticals, Inc.. It is currently in Phase 2 development. Also known as: Irinotecan, (CPT 11),(Camptosar®), Erbitux (cetuximab).

At a glance

Generic nameEZN-2208, Cetuximab and Irinotecan
Also known asIrinotecan, (CPT 11),(Camptosar®), Erbitux (cetuximab)
SponsorEnzon Pharmaceuticals, Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about EZN-2208, Cetuximab and Irinotecan

What is EZN-2208, Cetuximab and Irinotecan?

EZN-2208, Cetuximab and Irinotecan is a Small molecule drug developed by Enzon Pharmaceuticals, Inc..

Who makes EZN-2208, Cetuximab and Irinotecan?

EZN-2208, Cetuximab and Irinotecan is developed by Enzon Pharmaceuticals, Inc. (see full Enzon Pharmaceuticals, Inc. pipeline at /company/enzon-pharmaceuticals-inc).

Is EZN-2208, Cetuximab and Irinotecan also known as anything else?

EZN-2208, Cetuximab and Irinotecan is also known as Irinotecan, (CPT 11),(Camptosar®), Erbitux (cetuximab).

What development phase is EZN-2208, Cetuximab and Irinotecan in?

EZN-2208, Cetuximab and Irinotecan is in Phase 2.

Related